What Is GLP-1 Microdosing? How Lower Doses of Semaglutide and Tirzepatide Work

If you've spent any time in a menopause forum lately, you've watched this word take over. Microdosing gets credited with everything from effortless maintenance to quieter side effects to some vague promise of metabolic renewal, and most of what's written about it is either selling something or copied from something that was. Which is a shame, because underneath the marketing there's a genuinely reasonable clinical idea, one that happens to matter more for midlife women than for almost anyone else. So let's take it apart properly: what microdosing actually is, what the evidence does and doesn't support, and how to tell a thoughtful low-dose plan from an expensive guess.

What Microdosing Actually Means

Microdosing means using the same semaglutide or tirzepatide from the trials at doses below the standard schedule, in pursuit of the least medication that works rather than the most you can tolerate. To see why that's a real distinction and not marketing, look at what the standard schedules were built for. They exist to answer one question: how much weight can this drug remove at the highest dose a person can comfortably tolerate? That's what the big trials measured, and the answers were impressive, roughly 15% of body weight at semaglutide's full 2.4 mg dose and up to about 21% with tirzepatide.^[3][4] Every escalation ladder printed on every label exists in service of that number.

Microdosing asks a quieter and, for a lot of women, more relevant question: what's the least medication that keeps my appetite manageable and my weight where I want it? Same molecules, same mechanism, entirely different philosophy. Instead of climbing the ladder until side effects push back, you stay near the bottom, sometimes below the bottom rung entirely, and only move when your body gives you a reason to.

In practice that means somewhere around 0.1 to 0.5 mg weekly for semaglutide, or 0.5 to 2.5 mg for tirzepatide, though the numbers matter less than the intent. The women drawn to this approach tend to fall into three overlapping groups: those who've finished a weight-loss phase and would like to keep the result without staying on a full dose forever, those whose bodies respond so strongly that the standard schedule always felt like driving with the pedal floored, and those who never wanted dramatic weight loss in the first place, just relief from the food noise and appetite chaos that showed up somewhere in perimenopause and refused to leave.

What the Evidence Shows, and What It Doesn't

The short version: there's strong evidence these medications work and that stopping them causes regain, and no direct evidence yet about microdoses themselves. That lopsidedness is worth sitting with for a minute, because the average microdosing article would rather you didn't notice it.

What's well established: these medications work, and stopping them undoes the work. That second part matters more than people realize. In STEP 4, participants who were switched to placebo after five months of semaglutide regained most of what they'd lost, while those who stayed on it kept losing.^[5] SURMOUNT-4 ran the same experiment with tirzepatide and got the same answer, a 21% average loss largely surrendered within a year of stopping.^[6] Obesity researchers stopped being surprised by this long ago; appetite regulation is biology, and the biology reasserts itself when the medication leaves. So the case for some ongoing medication during maintenance is strong.

What nobody has established is the dose. The trials compared full dose against nothing, which leaves the entire territory in between, exactly where microdosing lives, unmapped. No published randomized trial has tested whether 0.25 mg of semaglutide holds a maintenance result, and when a Harvard endocrinologist reviewed the trend this year, the verdict was blunt: no legitimate long-term data, and no agreed definition of what microdosing even is.^[7] A registered trial is finally underway, which should start converting anecdote into evidence.^[8]

Until it does, an honest description goes like this: microdosing is what medicine calls a clinical extrapolation, which is essentially an educated bridge between two proven points. Doctors know the full dose works, they know stopping fails, and they reason their way into the unmapped territory in between using how these drugs behave in the body and a lot of accumulated experience with real patients. It should be treated as exactly that. Not fake, not proven, but plausible and monitorable. The monitoring is the part that makes it defensible, because your own response data does the job the missing trial hasn't done yet. Any program that hands you a fixed microdosing plan and disappears has skipped the only part that makes the whole idea legitimate.

Why This Matters More for Midlife Women

Midlife women are arguably the population microdosing was accidentally invented for, and the argument rests on three pieces of biology.

The first is that women respond more strongly to these medications than men do. When researchers went back through semaglutide trial data and separated results by sex, women had lost a greater percentage of body weight at the same dose.^[9] A standard ladder calibrated for the average trial participant will therefore overshoot for a meaningful share of women, delivering more weight loss than they wanted along with more nausea than anyone wants. For those women, a lower dose isn't a diluted version of the real treatment. It is the right-sized treatment.

The second is that midlife biology refuses to hold still. Estrogen decline reshapes appetite signaling, shifts fat storage toward the middle, and changes how side effects feel, and it does all of this unevenly, sometimes month to month. A dose that felt perfect in March can feel like too much or too little by August, through no failure of yours. Dosing plans with long holds and scheduled reviews were practically designed for this kind of moving target, and if you're also on hormone therapy, the two treatments deserve to be managed by the same brain.

The third is the muscle problem. Rapid weight loss after 50 takes muscle with it, not just fat, at an age when muscle and bone are already harder to keep than they were at 35. Slower loss on smaller doses, paired with enough protein and something heavy to lift, is one of the few levers that lets you lose fat while protecting the body you'll be living in at 70.

How Real Microdosing Is Actually Prescribed

Real microdosing is prescribed as a personalized, provider-documented dose, and the reason is a practical constraint that shapes everything else: the manufactured products don't come in micro-amounts. Wegovy's smallest pen is 0.25 mg, Zepbound's is 2.5 mg, and both fire their full contents in one press, with no dial and no half-dose setting.^[1][2] There are pen-based workarounds, staying at the lowest strengths long term or spacing doses further apart, and we've covered how providers handle those in the Wegovy and Zepbound guides.

True micro-increments, the 0.1 mg kind, exist through exactly one legitimate door: a prescriber documents that you, personally, need a dose the commercial products don't offer, and a licensed compounding pharmacy prepares it for you. That documented, patient-specific pathway is what remained lawful after the FDA spent 2025 shutting down the mass-market compounded copycats.^[10] The documentation isn't bureaucratic decoration, either. It's the actual line between personalized medicine and the checkbox-telehealth model the FDA is still busy dismantling, so if a company offers you a "personalized" microdose without a provider ever engaging with your particulars, you've learned everything you need to know about them.

And one firm safety line, because the internet keeps suggesting otherwise: none of this involves you splitting pens or drawing partial doses out of single-dose vials at your kitchen counter. The FDA has documented hospitalizations from people self-measuring semaglutide, drawing five to twenty times the intended dose, because syringe math under fluorescent lighting is exactly as error-prone as it sounds.^[11] If a dose requires you to do arithmetic, the plan is wrong.

A properly built plan is almost boring by comparison: a starting dose matched to your goal and history, holds of four to eight weeks or longer so the dose can prove itself, and changes triggered by what your body reports rather than by the calendar. The drug-specific frameworks live in our semaglutide schedule and tirzepatide schedule guides, with the dose tables themselves in the semaglutide chart and tirzepatide chart.

Is Microdosing Right for You?

It's a reasonable fit if you're maintaining a loss and want fewer side effects than your full dose gave you, if you're one of those strong responders for whom the standard schedule always overshot, or if what you mainly want is appetite control through the menopause transition rather than a transformation. It's a poor fit if you have substantial weight to lose, because that's precisely what the full-dose programs are built and proven for, or if you're not willing to do the check-ins that stand in for the evidence nobody has published yet.

You'll notice that sorting yourself into one of those groups requires knowing how your body responds, where your hormones are, and what your history allows, which is another way of saying it isn't a self-scoring exercise. It's an intake conversation, and it's the front door of Josie's microdose maintenance plans. Bring the question; a licensed provider brings the answer, and if the answer is no, a good one will tell you that too.